Bora Pharmaceuticals Co (保瑞藥業) has acquired six brand product licenses, rights and process technologies in the US for US$38.5 million, and expects them to start contributing to revenue in the fourth quarter of this year, the company said in a filing with the Taiwan Stock Exchange yesterday.
Bora’s board of directors approved the deal with Morristown, New Jersey-based Almatica Pharma Inc, as the Taiwanese firm moves into the brand product market to diversify risks away from generic drugs, the filing said.
The deal would enable Bora to leverage its sales platforms to enter the brand product market, it said.
Photo: CNA
Established in 2008, Almatica —a US subsidiary of Alvogen Group — focuses on the development, acquisition and commercialization of pharmaceutical products. Its product portfolio includes psychiatry, pain management, anti-infective and cardiovascular treatments, the company’s Web site says.
The six brand products are Zestril, Tenormin and Tenoretic for cardiovascular treatment, and Forfivo XL, Naprelan and Fluoxetine HCL for treating central nervous system issues, Bora said.
Sales of the six drugs in the US totaled about US$220 million last year, the company said, citing data from life sciences researcher Iqvia Institute.
As the deal was conducted through Bora’s subsidiary TWi Pharmaceuticals Inc (安成藥), it would greatly bolster the generic-drug unit’s product portfolio in the US market, while reducing its concentration on generic drugs, Bora chairman Bobby Sheng (盛保熙) told an investors’ conference in Taipei yesterday.
After TWi completes its takeover of the six products’ licenses and rights, it can deploy Bora group’s contract manufacturing and development expertise for mass production, which would not only increase TWi’s profit, but also boost the parent company’s global contract manufacturing business, Sheng said.
Bora’s second-quarter net profit surged 192 percent to NT$700.83 million (US$21.92 million) from NT$239.99 million in the same period last year. That translated into earnings per share (EPS) of NT$8.95, compared with NT$3.2 a year earlier.
EPS in the first half of the year was NT$22.54, up from NT$5.57 a year earlier, while gross margin improved to 46.09 percent, from 37.12 percent, it said.
With cumulative revenue in the first half of the year jumping 220.5 percent year-on-year to NT$7.92 billion and a better business outlook, the company yesterday raised its annual revenue growth forecast to between 30 and 35 percent, from its previous estimate of 20 to 30 percent.
It also raised its gross margin forecast to between 45 and 50 percent, from its earlier projection of 45 percent.
Sweeping policy changes under US Secretary of Health and Human Services Robert F. Kennedy Jr are having a chilling effect on vaccine makers as anti-vaccine rhetoric has turned into concrete changes in inoculation schedules and recommendations, investors and executives said. The administration of US President Donald Trump has in the past year upended vaccine recommendations, with the country last month ending its longstanding guidance that all children receive inoculations against flu, hepatitis A and other diseases. The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a drag that would likely dent revenues and
Global semiconductor stocks advanced yesterday, as comments by Nvidia Corp chief executive officer Jensen Huang (黃仁勳) at Davos, Switzerland, helped reinforce investor enthusiasm for artificial intelligence (AI). Samsung Electronics Co gained as much as 5 percent to an all-time high, helping drive South Korea’s benchmark KOSPI above 5,000 for the first time. That came after the Philadelphia Semiconductor Index rose more than 3 percent to a fresh record on Wednesday, with a boost from Nvidia. The gains came amid broad risk-on trade after US President Donald Trump withdrew his threat of tariffs on some European nations over backing for Greenland. Huang further
Nvidia Corp’s GB300 platform is expected to account for 70 to 80 percent of global artificial intelligence (AI) server rack shipments this year, while adoption of its next-generation Vera Rubin 200 platform is to gradually gain momentum after the third quarter of the year, TrendForce Corp (集邦科技) said. Servers based on Nvidia’s GB300 chips entered mass production last quarter and they are expected to become the mainstay models for Taiwanese server manufacturers this year, Trendforce analyst Frank Kung (龔明德) said in an interview. This year is expected to be a breakout year for AI servers based on a variety of chips, as
HSBC Bank Taiwan Ltd (匯豐台灣商銀) and the Taiwan High Prosecutors Office recently signed a memorandum of understanding (MOU) to enhance cooperation on the suspicious transaction analysis mechanism. This landmark agreement makes HSBC the first foreign bank in Taiwan to establish such a partnership with the High Prosecutors Office, underscoring its commitment to active anti-fraud initiatives, financial inclusion, and the “Treating Customers Fairly” principle. Through this deep public-private collaboration, both parties aim to co-create a secure financial ecosystem via early warning detection and precise fraud prevention technologies. At the signing ceremony, HSBC Taiwan CEO and head of banking Adam Chen (陳志堅)
RSS